Regards prescription drugs and medication switching
SB 160 prohibits health insurance plans from making certain changes to drug coverage during a plan year, such as increasing patient costs, moving drugs to more restrictive tiers, or removing drugs from formularies (except for specific safety or manufacturer discontinuation reasons). It directly affects health insurance issuers and plan members by limiting how insurers can adjust coverage for prescription drugs. Key provisions include allowing generic substitution when available, preventing prior authorization for covered drugs, and exempting plans from restrictions if a drug’s cost rises more than 5% plus inflation. The bill aims to stabilize drug access for patients while permitting standard practices like formulary additions and generic substitutions.
Bill status
passed
3 of 5 stages cleared
Introduction
Apr 2025
Committee Review
Apr 2025
Senate Passage
Jun 2026
House Passage
Governor
Introduced Apr 1, 2025
Last action Jun 16, 2026
Maddy AI version diff · 1 comparison
What changed between versions
As Introduced
→
As Passed by the Senate
·
4 edits
·
Jun 10, 2026
MODERATE
The bill was amended to clarify that health plans cannot move drugs to 'greater' cost-share tiers rather than just 'more restrictive' ones. It added a specific exception allowing plans to impose new prior authorization requirements for drugs that were not previously subject to such requirements within the same plan year. Additionally, the bill now explicitly permits pharmacists to substitute epinephrine autoinjectors, which was previously only implied.
Scope change
The bill's scope was expanded to explicitly include new prior authorization requirements as a prohibited action, whereas the original text only covered limiting or reducing existing coverage.
REQUIREMENT
Changed the prohibition on moving drugs from 'more restrictive tier' to 'greater cost-share tier' to ensure consistent terminology regarding cost-sharing levels.
Added a specific exception allowing health plans to subject a drug to a new prior authorization requirement during a plan year if the drug had not previously been subject to such a requirement.
Explicitly clarified that the bill does not prevent pharmacists from substituting one epinephrine autoinjector for another, removing ambiguity about this specific substitution.
TECHNICAL
Added a new section stating that the bill applies to health benefit plans delivered, issued, modified, or renewed on or after January 1, 2028.
Floor votes · Senate Jun 11, 2026
How they voted
33–0
Passed
Total votes 33
Jun 11, 2026
D
Democratic9
100% Yea
R
Republican24
100% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
6
Key actions
2
Committee
1
Jun 16, 2026
Introduced
Introduced
lower
Jun 11, 2026
Senate · Passed
Senate Vote: pass (33-0)
senate
Jun 10, 2026
Upper · Passed
Passed
upper
Apr 2, 2025
Committee
Referred to committee
upper
Apr 1, 2025
Introduced
Introduced
upper
2 primary · 0 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about SB 160
Scope: OH
Hi! I can help you understand SB 160. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline